FILING ANALYSIS · TUESDAY, NOVEMBER 10
CalciMedica, Inc. CALC — 8-K: Results of Operations and Financial Condition
neutral
CalciMedica's cash position of $13.8 million is expected to fund operations into the second half of 2027, and the company anticipates multiple catalysts over the next 12 months, including Auxora Phase 1b proof-of-concept data in pulmonary hypertension and CM5480 IND submission, both in mid-2027. However, there are no quantified surprises in the filing, such as earnings or guidance beats, or a conf
How we read impact: we grade every directional call in the open. Impact labels are AI estimates — not investment advice. See the full disclaimer.
Get filings like this every market day
The US SEC filings, UK RNS, EU notices, and Polymarket odds that matter — scored by AI, in one email.
Subscribe free →